Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Subscribe To Our Newsletter & Stay Updated
